Min Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Min Wang has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Xianwen Wang
Anhui Medical University
3 shared publications - Baolong Wang
Department of Laboratory Medicine, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230001, China.
1 shared publication - Dasheng Tian1 shared publication
- Erxu Tao1 shared publication
- Fei Huang
Department of orthopaedics, The Second Affiliated Hospital of Anhui Medical University, Hefei 230601, China; Institute of Orthopaedics, Research Center for Translational Medicine, The Second Affiliated Hospital of Anhui Medical University, Hefei 230601, China.
1 shared publication Jianguo Niu
School of Biomedical Engineering, Anhui Medical University, Hefei, 230032, China
1 shared publication
Latest Publications
- Open Access
- 1 August 2026
- Published by KEAI Publishing in Bioactive Materials
- Vol. 62, 64-80
Copper phosphate nanozymes combat implant-related infections by inducing cuproptosis-like death and inhibiting the two-component system
Implant-related infections, characterized by recalcitrant biofilm formation, antibiotic resistance, and immune evasion, pose a severe clinical burden in orthopedics due to the limited therapeutic efficacy of conventional approaches. Addressing this challenge requires innovative strategies capable of simultaneously disrupting biofilms and overcoming bacterial defense mechanisms. To address this, we developed flower-like copper phosphate (CuP) nanozymes with dual enzymatic activities (peroxidase- and glutathione peroxidase-like) that synergistically eradicate biofilms for implant-related infections through cuproptosis-like death and two-component system (TCS) inhibition. In vitro antimicrobial experiments demonstrated that CuP nanozymes significantly inhibited and disrupted bacterial biofilms. These CuP nanozymes generate reactive oxygen species (ROS) while depleting glutathione (GSH), disrupting bacterial membranes, and disrupting metabolic processes such as the TCA cycle and glycolysis. Transcriptomic analysis revealed suppressed expression of oxidative phosphorylation genes and quorum-sensing regulators, confirming dual targeting of bacterial viability and communication. In vivo, CuP nanozymes effectively eliminated biofilm infections on implants, reduced inflammatory responses, and demonstrated excellent biocompatibility. By integrating enzymatic ROS amplification, metabolic interference, and TCS inhibition, this strategy offers a transformative approach to combat resistant implant infections, surpassing conventional therapies in both efficacy and safety.
- 1 August 2026
- Published by KEAI Publishing in Bioactive Materials
- Vol. 62, 64-80
Open AccessCopper phosphate nanozymes combat implant-related infections by inducing cuproptosis-like death and inhibiting the two-component system
Implant-related infections, characterized by recalcitrant biofilm formation, antibiotic resistance, and immune evasion, pose a severe clinical burden in orthopedics due to the limited therapeutic efficacy of conventional approaches. Addressing this challenge requires innovative strategies capable of simultaneously disrupting biofilms and overcoming bacterial defense mechanisms. To address this, we developed flower-like copper phosphate (CuP) nanozymes with dual enzymatic activities (peroxidase- and glutathione peroxidase-like) that synergistically eradicate biofilms for implant-related infections through cuproptosis-like death and two-component system (TCS) inhibition. In vitro antimicrobial experiments demonstrated that CuP nanozymes significantly inhibited and disrupted bacterial biofilms. These CuP nanozymes generate reactive oxygen species (ROS) while depleting glutathione (GSH), disrupting bacterial membranes, and disrupting metabolic processes such as the TCA cycle and glycolysis. Transcriptomic analysis revealed suppressed expression of oxidative phosphorylation genes and quorum-sensing regulators, confirming dual targeting of bacterial viability and communication. In vivo, CuP nanozymes effectively eliminated biofilm infections on implants, reduced inflammatory responses, and demonstrated excellent biocompatibility. By integrating enzymatic ROS amplification, metabolic interference, and TCS inhibition, this strategy offers a transformative approach to combat resistant implant infections, surpassing conventional therapies in both efficacy and safety.
- Open Access
- 29 January 2026
- Published by Elsevier in Materials Today Bio
- Vol. 37, 102873
Strontium-luteolin nanoparticles promote M2 macrophage polarization and accelerate acute wound healing via immune microenvironment regulation
- 29 January 2026
- Published by Elsevier in Materials Today Bio
- Vol. 37, 102873
Open AccessStrontium-luteolin nanoparticles promote M2 macrophage polarization and accelerate acute wound healing via immune microenvironment regulation
- Open Access
- 26 March 2025
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 23 (1) , 1-22
Extracellular vesicles: a new frontier in diagnosing and treating graft-versus-host disease after allogeneic hematopoietic cell transplantation
Graft-versus-host disease (GvHD) is a prevalent complication following allogeneic hematopoietic stem cell transplantation (HSCT) and is characterized by relatively high morbidity and mortality rates. GvHD can result in extensive systemic damage in patients following allogeneic HSCT (allo-HSCT), with the skin, gastrointestinal tract, and liver frequently being the primary target organs affected. The severe manifestations of acute intestinal GvHD often indicate a poor prognosis for patients after allo-HSCT. Endoscopy and histopathological evaluation remain employed to diagnose GvHD, and auxiliary examinations exclude differential diagnoses. Currently, reliable serum biomarkers for the diagnosis and differential diagnosis of GvHD are scarce. As an essential part of standard transplant protocols, early application of immunosuppressive drugs effectively prevents GvHD. Among them, steroids represent first-line therapeutic agents, and the JAK2 inhibitor ruxolitinib represents the second-line therapeutic agent. Currently, no efficacious treatment modality exists for steroid-resistant aGvHD. Therefore, the diagnosis and treatment of GvHD still face significant medical demands. Extracellular vesicles (EVs) are nanometer to micrometer-scale biomembrane vesicles containing various bioactive components, such as proteins, nucleotides, and metabolites. Distinctive changes in serum-derived EV components occur in patients after allo-HSCT; Hence, EVs are expected to be potential biomarkers for diagnosing and treating GvHD. Furthermore, cell-free therapeutics characterized by EVs derived from mesenchymal stem cells (MSCs) have manifested remarkable therapeutic efficacy in preclinical models and preclinical trials of GvHD. Customized engineered EVs with fewer toxic and side effects for the combined treatment of GvHD hold broad prospects for clinical translation. This review article examines the potential value of translating EVs into clinical applications for the diagnosis and treatment of GvHD. It summarizes the latest advancements and prospects of engineered EVs applying GvHD.
- 26 March 2025
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 23 (1) , 1-22
Open AccessExtracellular vesicles: a new frontier in diagnosing and treating graft-versus-host disease after allogeneic hematopoietic cell transplantation
Graft-versus-host disease (GvHD) is a prevalent complication following allogeneic hematopoietic stem cell transplantation (HSCT) and is characterized by relatively high morbidity and mortality rates. GvHD can result in extensive systemic damage in patients following allogeneic HSCT (allo-HSCT), with the skin, gastrointestinal tract, and liver frequently being the primary target organs affected. The severe manifestations of acute intestinal GvHD often indicate a poor prognosis for patients after allo-HSCT. Endoscopy and histopathological evaluation remain employed to diagnose GvHD, and auxiliary examinations exclude differential diagnoses. Currently, reliable serum biomarkers for the diagnosis and differential diagnosis of GvHD are scarce. As an essential part of standard transplant protocols, early application of immunosuppressive drugs effectively prevents GvHD. Among them, steroids represent first-line therapeutic agents, and the JAK2 inhibitor ruxolitinib represents the second-line therapeutic agent. Currently, no efficacious treatment modality exists for steroid-resistant aGvHD. Therefore, the diagnosis and treatment of GvHD still face significant medical demands. Extracellular vesicles (EVs) are nanometer to micrometer-scale biomembrane vesicles containing various bioactive components, such as proteins, nucleotides, and metabolites. Distinctive changes in serum-derived EV components occur in patients after allo-HSCT; Hence, EVs are expected to be potential biomarkers for diagnosing and treating GvHD. Furthermore, cell-free therapeutics characterized by EVs derived from mesenchymal stem cells (MSCs) have manifested remarkable therapeutic efficacy in preclinical models and preclinical trials of GvHD. Customized engineered EVs with fewer toxic and side effects for the combined treatment of GvHD hold broad prospects for clinical translation. This review article examines the potential value of translating EVs into clinical applications for the diagnosis and treatment of GvHD. It summarizes the latest advancements and prospects of engineered EVs applying GvHD.
- Open Access
- 28 September 2024
- Vol. 5 (3) , 331-333
The potential of three-dimensional printed stents in post-operative treatment of breast cancer
- 28 September 2024
- Vol. 5 (3) , 331-333
Open AccessThe potential of three-dimensional printed stents in post-operative treatment of breast cancer